Head to Head Review: Butterfly Network vs. Standard BioTools

Comparing the small-cap medical companies on key metrics

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Butterfly Network (NYSE:BFLY) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which one is the better stock? This article compares the two companies based on factors like institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, and dividends.

Why it matters

Investors looking to gain exposure to the medical technology sector may be interested in comparing these two small-cap companies to determine which one presents a more attractive investment opportunity.

The details

The analysis found that Butterfly Network has a stronger consensus rating from analysts, with a price target indicating 71.85% potential upside compared to 17.39% for Standard BioTools. Butterfly Network also has higher earnings, a lower price-to-earnings ratio, and better profitability metrics like net margins, return on equity, and return on assets. However, Butterfly Network's stock is also more volatile, with a beta of 2.27 compared to 1.29 for Standard BioTools.

  • The analysis is based on data reported as of February 20, 2026.

The players

Butterfly Network

A medical technology company that develops and commercializes ultrasound imaging solutions.

Standard BioTools

A medical technology company that provides instruments, consumables, reagents, and software services for researchers and clinical laboratories.

Got photos? Submit your photos here. ›

The takeaway

Investors evaluating small-cap medical technology stocks may find Butterfly Network to be the more favorable investment based on its stronger analyst consensus, higher earnings, and better profitability, though its higher volatility should also be considered.